{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'wellbeing, discuss compliance (if applicable), proper recording of attack details (if applicable),', 'or any usability issues with the e-diary. A weekly phone call may be omitted if the subject', 'records an attack as the Investigator must call and confirm or reject the attack.', '10.3.3.2. Week 2 Visit', 'The Week 2 visit will consist of monitoring liver function tests only (ALT, AST, GGT, total and', 'direct bilirubin, alkaline phosphatase [ALP]); urine and additional tubes of blood may be', 'required to accommodate reflex testing for abnormal GGT, AST, or ALT (see Table 5). If', 'preferred by the subject and clinical site, laboratory values may be drawn and resulted locally,', 'with results entered into the CRF.', 'During Part 1, Investigators will contact subjects to confirm all HAE attacks recorded in the', 'e-diary within approximately 2 business days of the end of the attack. Moreover, any', 'noncompliance will warrant contact with the subject.', '10.3.3.3. Week 4, 8, 12, and 18 Visits', 'Subjects will return to the clinic during Week 4 (Day 29 2 days), Week 8 (Day 57 2 days),', 'Week 12 (Day 85 2 days), and Week 18 (Day 127 2 days).', 'Subjects do not need to withhold any doses on clinic days or take a dose in the clinic, unless the', \"clinic visit falls during the subject's normal time of dosing.\", 'The following assessments will be performed:', 'Administration of EQ-5D-5L (1 or 2 questionnaires), AE-QoL, TSQM, and WPAI', 'questionnaires. Where possible, the questionnaires should be completed by the', 'subject prior to other assessments to prevent influencing subject perceptions.', 'Subject weight', 'Vital signs (blood pressure and pulse rate)', '12-lead ECG (single assessments)', 'Abbreviated physical examination (targeted to new signs and symptoms)', 'Blood collection for clinical chemistry, hematology, and coagulation, Troponin I and', 'Troponin T, NGAL, and CK-MB', 'PK and PD plasma samples', 'Urine collection for urinalysis, possible reflex testing for abnormal GGT, AST, or', 'ALT and urine pregnancy test for female subjects of childbearing potential', 'Review of concomitant medications and AEs', 'Review of HAE attack and dosing diary completion and study drug compliance', 'Study drug accountability and dispensing', 'During the Part 1 dosing period, Investigators will contact subjects to confirm all HAE attacks', 'recorded in the e-diary within approximately 2 business days of the end of the attack. Moreover,', 'any noncompliance will warrant contact with the subject.', '66']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'The Investigator (or designee) must call and talk to the subject at least weekly; alternative forms', 'of interactive communication such as returned email and cellular text correspondence are', \"acceptable. During all calls, the Investigator (or designee) will assess the subject's overall\", 'wellbeing, discuss compliance (if applicable), proper recording of attack details (if applicable),', 'or any usability issues with the e-diary. A weekly phone call may be omitted if the subject', 'records an attack as the Investigator must call and confirm or reject the attack.', 'At the Week 12 and 18 visits, sites in Europe will dispense urinary pregnancy tests to subjects', 'who are women of childbearing potential. These will be completed by the subject at home at', 'Weeks 16 and 22.', 'At the Week 18 visit and during phone calls prior to Week 24, subjects will be instructed to take', 'their last dose of study drug on Day 168, the day prior to the Week 24 visit.', '10.3.3.4. Week 24 Visit', 'The Week 24 visit will be conducted on Day 169, the day after the last dose of study drug in', 'Part 1. Before any study drug for Part 2 is administered the following assessments will be', 'completed:', 'Administration of EQ-5D-5L (1 or 2 questionnaires), AE-QoL, TSQM, and WPAI', 'questionnaires. Where possible, the questionnaires should be completed by the', 'subject prior to other assessments to prevent influencing subject perceptions.', 'Subject weight', 'Vital signs (blood pressure, temperature, respiratory rate, and pulse rate)', '12-lead ECG (in triplicate)', 'Complete physical examination', 'Blood collection for clinical chemistry, hematology, and coagulation, Troponin I and', 'Troponin T, NGAL, and CK-MB', 'PK and PD plasma samples', 'Urine collection for urinalysis, possible reflex testing for abnormal GGT, AST, or', 'ALT and urine pregnancy test for female subjects of child-bearing potential. A', 'negative urine pregnancy result must be recorded for the subject to be dosed.', 'Review of concomitant medications and AEs', 'Part 1 study drug collection/accountability', 'e-diary instruction and review', 'After completion of the above bulleted items, subjects may be randomized at the conclusion of', 'the visit. Part 2 study drug may then be dispensed and accountability performed. The first dose of', 'study drug in Part 2 may be administered (if timing coincides with typical dosing time, see', 'Section 9.3.2). Study drug in Part 2, if not taken during the visit, should be taken the day of the', 'visit at home.', '67']\n\n###\n\n", "completion": "END"}